Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Invivyd, Inc. filings document material events, governance matters, capital actions, and financial-result disclosures for a Nasdaq-listed biopharmaceutical company developing monoclonal antibodies for serious viral infectious diseases. Recent Form 8-K reports furnish operating results, preliminary product revenue information for PEMGARDA, corporate presentations, and program updates involving COVID-19, RSV, and measles antibody candidates.
The filing record also includes a definitive proxy statement covering annual-meeting matters such as director elections and auditor ratification, as well as an 8-K describing a completed underwritten public offering of common stock and pre-funded warrants. These disclosures describe the company’s common stock, financing activity, board governance, research and development priorities, and commercial preparedness around its antibody portfolio.
Invivyd, Inc. received an updated ownership report showing that investment firms associated with Point72 and Steven A. Cohen beneficially own 16,653,036 shares of its common stock, representing 6.0% of the company as of December 31, 2025.
The shares are held by Point72 Associates, LLC, with investment and voting power managed by Point72 Asset Management, L.P., while Point72 Capital Advisors, Inc. is its general partner and Mr. Cohen controls both entities. The reported percentage is based on 277,064,852 shares outstanding as of the completion of Invivyd’s underwritten public offering that closed on November 17, 2025. The reporting parties state the securities were not acquired to change or influence control of Invivyd.
Invivyd, Inc. received an updated ownership report from Biotechnology Value Fund and related entities, which together may be deemed to beneficially own 25,525,000 shares of Invivyd common stock, or approximately 9.0% of the company, as of December 31, 2025. This includes holdings of Pre-Funded Warrants exercisable for 6,000,000 shares at an exercise price of $0.0001 per share, subject to a 9.99% ownership blocker that limits exercises above that threshold. The group states the securities are not held for the purpose of changing or influencing control of Invivyd, outside of activities solely in connection with a nomination under relevant proxy rules.
Maverick Capital and related entities report a passive stake in Invivyd, Inc. (IVVD). As of December 31, 2025, Maverick Capital, Ltd., Maverick Capital Management, LLC, and Lee S. Ainslie III collectively report beneficial ownership of 18,970,913 shares of Invivyd common stock, representing 6.7% of the outstanding shares, based on 281,987,033 shares reported by the company. The shares are held in client accounts of Maverick-managed funds, and the filers certify that the holdings were not acquired to change or influence control of Invivyd.
Invivyd, Inc. (IVVD) received an amended Schedule 13G showing that a group of Soleus-affiliated investment entities and Guy Levy collectively report beneficial ownership below 5% of its common stock. The filing is based on an event dated December 31, 2025.
Soleus Private Equity Fund III, L.P. and related Soleus private equity entities each report beneficial ownership of 1,680,160 shares, representing 0.6% of Invivyd’s common stock. Separately, Soleus Capital Master Fund, L.P. and related Soleus capital entities each report 6,028,567 shares, or 2.2% of the class.
Soleus Capital Management, L.P., Soleus GP, LLC and Guy Levy each report beneficial ownership of 7,708,727 shares, equal to 2.8% of Invivyd’s outstanding common stock, all with shared and no sole voting or dispositive power. The percentages are calculated using 277,064,852 Invivyd shares outstanding immediately after an underwritten offering described in a prospectus supplement. The reporting persons state the securities were not acquired and are not held for the purpose of changing or influencing control of Invivyd.
Invivyd, Inc.’s Chief Financial Officer William E. Duke received a new stock option grant. On January 29, 2026, he was awarded options to purchase 625,000 shares of Invivyd common stock at an exercise price of $1.85 per share.
The options vest over three years, with 1/36th of the total vesting in substantially equal monthly installments starting one month after the grant date, contingent on his continuous service with the company.
Invivyd, Inc. reported that Chief Human Resources Officer Julie Green received a grant of stock options on January 29, 2026. The award covers 675,000 options to buy common stock at an exercise price of $1.85 per share, with no cash paid for the grant itself.
The options vest over three years, with 1/36th of the grant vesting in substantially equal monthly installments starting one month after the grant date, contingent on her continued service. Following this award, she holds 675,000 stock options directly.
Invivyd, Inc. reported a new equity award to its Chief Commercial Officer, Timothy Edward Lee. On January 29, 2026, he received a stock option to purchase 675,000 shares of common stock at an exercise price of $1.85 per share.
The option vests over three years, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, subject to his continuous service at each vesting date. Following this grant, he beneficially owns 675,000 derivative securities directly.
Invivyd, Inc. reported that its Chief Legal Officer and Secretary, Jill Andersen, received a new stock option award. On January 29, 2026, she was granted an option to buy 820,000 shares of Invivyd common stock at an exercise price of $1.85 per share.
The option vests over three years, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, conditioned on her continued service. After this grant, she beneficially owns 820,000 stock options directly.
Invivyd, Inc. granted a large stock option award to its Chief Scientific Officer. On January 29, 2026, Allen Robert D. III received a stock option covering 625,000 shares of Invivyd common stock at an exercise price of $1.85 per share.
The option vests over three years, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, conditioned on his continued service on each vesting date. Following this grant, he beneficially owns 625,000 derivative securities directly.
Invivyd, Inc. filed a current report describing a new press release that shares preliminary fourth quarter 2025 PEMGARDA® (pemivibart) net product revenue and the company’s cash and cash equivalents as of December 31, 2025. These figures are early management estimates and may change after Invivyd completes its financial closing procedures and finalizes its audited financial statements for the quarter and full year 2025.
The company explains that the preliminary data have not been audited by its independent registered public accounting firm and that additional information will be needed for a full picture of its financial position and results of operations. Invivyd also filed the full press release as an exhibit and made an updated corporate presentation available on its website, providing investors with recent business highlights alongside the early financial indicators.